What does high testosterone mean in a woman?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
A mildly raised testosterone in a woman most often reflects PCOS, which accounts for the large majority of androgen excess. The result only means something if it was measured correctly: by mass spectrometry, in the morning, and off the combined oral contraceptive pill. Rapid onset over months, or voice deepening and clitoral enlargement, points somewhere else.
Testosterone is a normal female hormone. Women produce it in the ovaries and adrenal glands, at roughly a tenth to a twentieth of male concentrations, and it contributes to libido, muscle and bone. A high result matters in context: what the symptoms are, how fast they appeared, and whether the assay was capable of measuring female-range concentrations accurately. PCOS is by far the commonest explanation for a mild elevation.
How it should be measured
The 2023 International Evidence-based Guideline recommends total and free testosterone to assess biochemical hyperandrogenism, with free testosterone estimated by the calculated free androgen index. It also recommends that laboratories use validated LC-MS/MS assays for total testosterone, because direct immunoassays are unreliable at female concentrations. Direct free testosterone immunoassays should not be used. Sampling is in the morning, and androgens cannot be interpreted at all on a combined oral contraceptive pill, which raises sex hormone binding globulin.
What causes a genuinely high result
PCOS accounts for most cases. Nonclassic congenital adrenal hyperplasia is the main alternative and is screened with an early morning 17-hydroxyprogesterone taken in the follicular phase. If total and free testosterone are not elevated but the picture still fits, the guideline says androstenedione and DHEA-S could be measured, while noting their limited additional value. Cushing syndrome, certain medications and, rarely, an androgen-producing tumour of the ovary or adrenal gland complete the list.
When the pattern is concerning
Speed and severity are the two features that change the workup. Androgen excess from PCOS builds gradually over years. Symptoms that appear over a few months, or that include voice deepening, clitoral enlargement, male pattern balding or muscle bulking, warrant prompt evaluation for an androgen-secreting tumour, with imaging of the ovaries and adrenal glands. That combination is uncommon, but it is the reason a clinician asks how quickly things changed.
| Pattern | Typical cause | Next step |
|---|---|---|
| Gradual over years, irregular cycles | PCOS | Confirm criteria, screen metabolically |
| Since adolescence, family history, certain ancestries | Nonclassic congenital adrenal hyperplasia | Early morning 17-hydroxyprogesterone |
| Rapid onset with virilisation | Androgen-secreting tumour | Prompt imaging and specialist referral |
| Weight gain, bruising, proximal weakness | Cushing syndrome | Cortisol screening test |
If you have a high testosterone result, check three things before drawing conclusions: was it total or free, was it a mass spectrometry assay, and were you on hormonal contraception at the time. A result taken on the pill, or by a direct free testosterone immunoassay, may need repeating before it can be used.
The clinical detail
2023 guideline recommendations: total and free testosterone for biochemical hyperandrogenism, free testosterone by calculated free androgen index (1.2.1); validated LC-MS/MS assays for total testosterone (1.2.3); androstenedione and DHEA-S considered only if testosterone is not elevated (1.2.2); androgens uninterpretable on the combined oral contraceptive pill (1.2.6). Allow at least three months off the pill before testing.
The free androgen index is calculated as total testosterone divided by sex hormone binding globulin, multiplied by 100, using nmol/L units for both. Because it depends on SHBG, it moves with insulin resistance, thyroid status, oestrogen and liver disease, which is exactly why it is informative in PCOS. Reference ranges differ between laboratories and assays, so compare a result to the range printed on that report rather than to a number from elsewhere.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Endocrine Society. PMID 29522147
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- Polycystic ovary syndrome: an update on diagnosis and management (2026). Cleveland Clinic Journal of Medicine
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.